Use of Tissue Specimens from Stereotactic Biopsies for Patient-Derived GBM Organoid-Based Drug Testing
<i>IDH</i>-wildtype glioblastoma (GBM) represents the most common malignant form of brain tumor and is still incurable despite comprehensive therapeutic efforts. Due to tumor location and patient condition, open surgical resection of recurrent GBM is not always feasible. In these cases,...
Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-05-01
|
| Series: | Cells |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2073-4409/14/10/701 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849327408627318784 |
|---|---|
| author | Amélie Wöllner Adrian Paul Maddalena Arquilla Junguo Cao Catharina Lotsch Gerhard Jungwirth Lena Jassowicz Andreas von Deimling Andreas W. Unterberg Sandro M. Krieg Martin Jakobs Rolf Warta Christel Herold-Mende |
| author_facet | Amélie Wöllner Adrian Paul Maddalena Arquilla Junguo Cao Catharina Lotsch Gerhard Jungwirth Lena Jassowicz Andreas von Deimling Andreas W. Unterberg Sandro M. Krieg Martin Jakobs Rolf Warta Christel Herold-Mende |
| author_sort | Amélie Wöllner |
| collection | DOAJ |
| description | <i>IDH</i>-wildtype glioblastoma (GBM) represents the most common malignant form of brain tumor and is still incurable despite comprehensive therapeutic efforts. Due to tumor location and patient condition, open surgical resection of recurrent GBM is not always feasible. In these cases, frame-based stereotactic biopsies represent a less invasive technique to obtain tissue samples for diagnostics. However, whether this material would also be sufficient to prepare tumor organoids (TOs) and perform drug screenings has not been addressed so far. In this study, we present our highly optimized workflow for generating standardized patient-derived GBM TOs from single-cell suspensions using limited biopsy-derived material. We highlight crucial steps within the procedure, such as reliable cell counting, viable cell recovery, enzymatic digestion, and the requirement of an extracellular matrix as a scaffold. Furthermore, we showcase the potential of personalized drug testing as a promising application of GBM TOs. In conclusion, we successfully developed a robust workflow that effectively utilizes the limited material derived from stereotactic biopsies to reproducibly form standardized TOs. Moreover, we demonstrate that biopsy-derived TOs represent a valuable tool for testing drug vulnerabilities in a personalized setting, which might be especially useful in the case of non-resectable GBM. |
| format | Article |
| id | doaj-art-a263c54aea784834bf13768d35e09a8a |
| institution | Kabale University |
| issn | 2073-4409 |
| language | English |
| publishDate | 2025-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cells |
| spelling | doaj-art-a263c54aea784834bf13768d35e09a8a2025-08-20T03:47:53ZengMDPI AGCells2073-44092025-05-01141070110.3390/cells14100701Use of Tissue Specimens from Stereotactic Biopsies for Patient-Derived GBM Organoid-Based Drug TestingAmélie Wöllner0Adrian Paul1Maddalena Arquilla2Junguo Cao3Catharina Lotsch4Gerhard Jungwirth5Lena Jassowicz6Andreas von Deimling7Andreas W. Unterberg8Sandro M. Krieg9Martin Jakobs10Rolf Warta11Christel Herold-Mende12Division of Experimental Neurosurgery, Department of Neurosurgery, Medical Faculty of Heidelberg, University of Heidelberg, 69120 Heidelberg, GermanyDivision of Experimental Neurosurgery, Department of Neurosurgery, Medical Faculty of Heidelberg, University of Heidelberg, 69120 Heidelberg, GermanyDivision of Experimental Neurosurgery, Department of Neurosurgery, Medical Faculty of Heidelberg, University of Heidelberg, 69120 Heidelberg, GermanyDivision of Experimental Neurosurgery, Department of Neurosurgery, Medical Faculty of Heidelberg, University of Heidelberg, 69120 Heidelberg, GermanyDivision of Experimental Neurosurgery, Department of Neurosurgery, Medical Faculty of Heidelberg, University of Heidelberg, 69120 Heidelberg, GermanyDivision of Experimental Neurosurgery, Department of Neurosurgery, Medical Faculty of Heidelberg, University of Heidelberg, 69120 Heidelberg, GermanyDivision of Experimental Neurosurgery, Department of Neurosurgery, Medical Faculty of Heidelberg, University of Heidelberg, 69120 Heidelberg, GermanyDepartment of Neuropathology, Medical Faculty of Heidelberg, University of Heidelberg, 69120 Heidelberg, GermanyDivision of Experimental Neurosurgery, Department of Neurosurgery, Medical Faculty of Heidelberg, University of Heidelberg, 69120 Heidelberg, GermanyDivision of Experimental Neurosurgery, Department of Neurosurgery, Medical Faculty of Heidelberg, University of Heidelberg, 69120 Heidelberg, GermanyDivision for Stereotactic Neurosurgery, Department of Neurosurgery, Medical Faculty of Heidelberg, University of Heidelberg, 69120 Heidelberg, GermanyDivision of Experimental Neurosurgery, Department of Neurosurgery, Medical Faculty of Heidelberg, University of Heidelberg, 69120 Heidelberg, GermanyDivision of Experimental Neurosurgery, Department of Neurosurgery, Medical Faculty of Heidelberg, University of Heidelberg, 69120 Heidelberg, Germany<i>IDH</i>-wildtype glioblastoma (GBM) represents the most common malignant form of brain tumor and is still incurable despite comprehensive therapeutic efforts. Due to tumor location and patient condition, open surgical resection of recurrent GBM is not always feasible. In these cases, frame-based stereotactic biopsies represent a less invasive technique to obtain tissue samples for diagnostics. However, whether this material would also be sufficient to prepare tumor organoids (TOs) and perform drug screenings has not been addressed so far. In this study, we present our highly optimized workflow for generating standardized patient-derived GBM TOs from single-cell suspensions using limited biopsy-derived material. We highlight crucial steps within the procedure, such as reliable cell counting, viable cell recovery, enzymatic digestion, and the requirement of an extracellular matrix as a scaffold. Furthermore, we showcase the potential of personalized drug testing as a promising application of GBM TOs. In conclusion, we successfully developed a robust workflow that effectively utilizes the limited material derived from stereotactic biopsies to reproducibly form standardized TOs. Moreover, we demonstrate that biopsy-derived TOs represent a valuable tool for testing drug vulnerabilities in a personalized setting, which might be especially useful in the case of non-resectable GBM.https://www.mdpi.com/2073-4409/14/10/701glioblastomapatient-derived tumor organoidsstereotactic biopsyprecision medicine |
| spellingShingle | Amélie Wöllner Adrian Paul Maddalena Arquilla Junguo Cao Catharina Lotsch Gerhard Jungwirth Lena Jassowicz Andreas von Deimling Andreas W. Unterberg Sandro M. Krieg Martin Jakobs Rolf Warta Christel Herold-Mende Use of Tissue Specimens from Stereotactic Biopsies for Patient-Derived GBM Organoid-Based Drug Testing Cells glioblastoma patient-derived tumor organoids stereotactic biopsy precision medicine |
| title | Use of Tissue Specimens from Stereotactic Biopsies for Patient-Derived GBM Organoid-Based Drug Testing |
| title_full | Use of Tissue Specimens from Stereotactic Biopsies for Patient-Derived GBM Organoid-Based Drug Testing |
| title_fullStr | Use of Tissue Specimens from Stereotactic Biopsies for Patient-Derived GBM Organoid-Based Drug Testing |
| title_full_unstemmed | Use of Tissue Specimens from Stereotactic Biopsies for Patient-Derived GBM Organoid-Based Drug Testing |
| title_short | Use of Tissue Specimens from Stereotactic Biopsies for Patient-Derived GBM Organoid-Based Drug Testing |
| title_sort | use of tissue specimens from stereotactic biopsies for patient derived gbm organoid based drug testing |
| topic | glioblastoma patient-derived tumor organoids stereotactic biopsy precision medicine |
| url | https://www.mdpi.com/2073-4409/14/10/701 |
| work_keys_str_mv | AT ameliewollner useoftissuespecimensfromstereotacticbiopsiesforpatientderivedgbmorganoidbaseddrugtesting AT adrianpaul useoftissuespecimensfromstereotacticbiopsiesforpatientderivedgbmorganoidbaseddrugtesting AT maddalenaarquilla useoftissuespecimensfromstereotacticbiopsiesforpatientderivedgbmorganoidbaseddrugtesting AT junguocao useoftissuespecimensfromstereotacticbiopsiesforpatientderivedgbmorganoidbaseddrugtesting AT catharinalotsch useoftissuespecimensfromstereotacticbiopsiesforpatientderivedgbmorganoidbaseddrugtesting AT gerhardjungwirth useoftissuespecimensfromstereotacticbiopsiesforpatientderivedgbmorganoidbaseddrugtesting AT lenajassowicz useoftissuespecimensfromstereotacticbiopsiesforpatientderivedgbmorganoidbaseddrugtesting AT andreasvondeimling useoftissuespecimensfromstereotacticbiopsiesforpatientderivedgbmorganoidbaseddrugtesting AT andreaswunterberg useoftissuespecimensfromstereotacticbiopsiesforpatientderivedgbmorganoidbaseddrugtesting AT sandromkrieg useoftissuespecimensfromstereotacticbiopsiesforpatientderivedgbmorganoidbaseddrugtesting AT martinjakobs useoftissuespecimensfromstereotacticbiopsiesforpatientderivedgbmorganoidbaseddrugtesting AT rolfwarta useoftissuespecimensfromstereotacticbiopsiesforpatientderivedgbmorganoidbaseddrugtesting AT christelheroldmende useoftissuespecimensfromstereotacticbiopsiesforpatientderivedgbmorganoidbaseddrugtesting |